Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia.
Cat.No
A401
Name
Tafolecimab
Chemical Properties
CAS
2225109-03-3
Synonyms
IBI-306
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard: PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
